广济药业(000952) - 2024 Q2 - 季度业绩预告

Financial Performance - The estimated net profit for the first half of 2024 is projected to be a loss of between 106 million to 134 million yuan, compared to a loss of 25.8 million yuan in the same period last year, representing a decline of 310.78% to 419.29%[3] - The net profit after deducting non-recurring gains and losses is expected to be a loss of between 114 million to 142 million yuan, compared to a loss of 27.4 million yuan in the same period last year, indicating a decline of 315.83% to 417.96%[3] - Basic earnings per share are projected to be a loss of between 0.2996 yuan to 0.3787 yuan, compared to a loss of 0.0729 yuan per share in the same period last year[3] Reasons for Decline - The primary reasons for the decline in net profit include decreased demand for vitamins, particularly a drop in sales of the main product, vitamin B2, leading to reduced gross margins[5] - The company’s Jining facility is still in the process of optimizing production processes, resulting in underutilized capacity and higher production costs, contributing significantly to the losses[5] - Increased financing scale has led to higher interest expenses on borrowings, further impacting net profit negatively[5]